(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 11.66%
0.89% $ 5.67
@ $7.86
Emitido: 14 feb 2024 @ 15:07
Retorno: -27.82%
Señal anterior: feb 14 - 12:00
Señal anterior:
Retorno: 1.62 %
Live Chart Being Loaded With Signals
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases...
Stats | |
---|---|
Volumen de hoy | 1.57M |
Volumen promedio | 1.95M |
Capitalización de mercado | 466.27M |
EPS | $0 ( 2024-05-03 ) |
Próxima fecha de ganancias | ( $-0.650 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.81 |
ATR14 | $0.0110 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-02 | Lucera Erick | Buy | 25 966 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 35 300 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 106 000 | Stock Option (right to buy) |
2024-03-02 | Burkly Linda | Buy | 15 055 | Common Stock |
2024-03-02 | Burkly Linda | Buy | 74 400 | Stock Option (right to buy) |
INSIDER POWER |
---|
88.63 |
Last 95 transactions |
Buy: 4 455 498 | Sell: 157 736 |
Volumen Correlación
Editas Medicine Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
BROG | 0.916 |
HUGE | 0.915 |
RKDA | 0.906 |
WKHS | 0.899 |
PYCR | 0.898 |
CDZI | 0.897 |
MIRM | 0.895 |
JWEL | 0.888 |
NVIV | 0.886 |
BLRX | 0.87 |
10 Correlaciones Más Negativas | |
---|---|
RNLC | -0.876 |
BCOR | -0.876 |
EBACU | -0.872 |
JNCE | -0.868 |
EGLE | -0.865 |
HPLTU | -0.864 |
IVCB | -0.862 |
TZPSU | -0.862 |
MSSA | -0.86 |
GOOGL | -0.856 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Editas Medicine Inc Correlación - Moneda/Commodity
Editas Medicine Inc Finanzas
Annual | 2023 |
Ingresos: | $78.12M |
Beneficio Bruto: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2023 |
Ingresos: | $78.12M |
Beneficio Bruto: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2022 |
Ingresos: | $19.71M |
Beneficio Bruto: | $13.38M (67.85 %) |
EPS: | $-2.98 |
FY | 2021 |
Ingresos: | $25.54M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.85 |
Financial Reports:
No articles found.
Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico